logo
teal triangle graphic

R&D Pipeline

R&D Pipeline

Pipeline of Key Proprietary Product Candidates

We have a pipeline of product candidates in development for psychiatric and neurological disorders.

These programs are investigating treatments or indications that have not received approval from a health authority. The information presented is not intended to convey conclusions of safety or efficacy. There is no guarantee that the outcome of these studies will result in approval by a health authority.
  • Discovery
  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3

  • Olanzapine and samidorphan

    • Schizophrenia and Bipolar I Disorder (Pediatric)

      Phase 3

    Overview

    Olanzapine and samidorphan is a once-daily, oral atypical antipsychotic drug approved for adults in the U.S.

    Clinical Trials

    Olanzapine and samidorphan is currently being evaluated for pediatric use in a phase 3 study. For more information about this study, please visit enlightenyouthstudy.com (U.S. audiences only) or clinicaltrials.gov/study/NCT05303064.

  • ALKS 2680

    • Narcolepsy Type 1

      Phase 2

    • Narcolepsy Type 2

      Phase 2

    • Idiopathic Hypersomnia

      Phase 2

    Overview

    ALKS 2680 is an investigational, oral orexin 2 receptor agonist in development as a once-daily treatment for narcolepsy type 1, narcolepsy type 2 and idiopathic hypersomnia.

    Clinical Trials

    ALKS 2680 is currently being evaluated in Vibrance-1, a phase 2 study in adults with narcolepsy type 1, Vibrance-2, a phase 2 study in adults with narcolepsy type 2, and Vibrance-3, a phase 2 study in adults with idiopathic hypersomnia. Participants who complete one of the Vibrance studies have the option to continue in a long-term, open-label, safety study evaluating the safety of ALKS 2680 for up to two years.

    For more information about these studies, please visit vibrancestudies.com (for U.S. audiences only) or the respective clinicaltrials.gov listings:

  • ALKS 4510

    • Neuroscience Indications

      Phase 1

    Overview

    ALKS 4510 is an investigational orexin 2 receptor agonist in developement for the treatment of central nervous system disorders. It is currently being evaluted in a phase 1 study in healthy volunteers.

  • ALKS 7290

    • Neuroscience Indications

      Preclinical

    Overview

    ALKS 7290 is an investigational orexin 2 receptor agonist being evaluated preclinically for the treatment of central nervous system disorders.

Last updated: May 2025